Journal
NEOPLASIA
Volume 2, Issue 1-2, Pages 166-189Publisher
ELSEVIER SCIENCE INC
DOI: 10.1038/sj.neo.7900081
Keywords
magnetic resonance spectroscopic imaging (MRSI); prostate and brain cancer; metabolism; magnetic resonance imaging (MRI); morphology
Categories
Funding
- NATIONAL CANCER INSTITUTE [R01CA059897, R01CA079980, R29CA064667, R01CA059880] Funding Source: NIH RePORTER
- NCI NIH HHS [R01 CA079980, CA59897, CA64667, CA79980, R01 CA059880, R01 CA059897] Funding Source: Medline
Ask authors/readers for more resources
Clinical applications of magnetic resonance spectroscopic imaging (MRSI) for the study of brain and prostate cancer have expanded significantly over the past 10 years. Proton MRSI studies of the brain and prostate have demonstrated the feasibility of noninvasively assessing human cancers based on metabolite levels before and after therapy in a clinically reasonable amount of time, MRSI provides a unique biochemical window to study cellular metabolism noninvasively, MRSI studies have demonstrated dramatic spectral differences between normal brain tissue (low choline and high N-acetyl aspartate, NAA) and prostate (low choline and high citrate) compared to brain (low NAA, high choline) and prostate (low citrate, high choline) tumors. The presence of edema and necrosis in both the prostate and brain was reflected by a reduction of the intensity of all resonances due to reduced cell density. MRSI was able to discriminate necrosis (absence of all metabolites, except lipids and lactate) from viable normal tissue and cancer following therapy. The results of current MRSI studies also provide evidence that the magnitude of metabolic changes in regions of cancer before therapy as well as the magnitude and time course of metabolic changes after therapy can improve our understanding of cancer aggressiveness and mechanisms of therapeutic response. Clinically, combined MRI/MRSI has already demonstrated the potential for improved diagnosis, staging and treatment planning of brain and prostate cancer. Additionally, studies are under way to determine the accuracy of anatomic and metabolic parameters in providing an objective quantitative basis for assessing disease progression and response to therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available